DEFA14A: Patterson Companies to be Acquired by Patient Square Capital in $31.35 Per Share Deal

Patterson Companies has agreed to be acquired by Patient Square Capital for $31.35 per share, with the transaction expected to close in the fourth fiscal quarter of 2025.

Summary

• Patterson Companies has entered into a definitive agreement to be acquired by Patient Square Capital, a healthcare investment firm.
• The acquisition price is $31.35 per share.
• The transaction is expected to close in Patterson's fiscal fourth quarter of 2025.
• The company will prepare proxy materials and schedule a shareholder meeting to vote on the transaction.
• Regulatory filings will also be required.
• Patterson's day-to-day operations and FY25 goals remain unchanged.
• The company's purpose, vision, values, and service to customers will remain the same.
• The Employee Stock Purchase Program (ESPP) will continue until December 31, 2024, with shares receiving the merger consideration.
• No new ESPP offering periods will commence, and no new participants will be allowed.
• KSOP shares will be converted to cash within the 401k plan and reinvested in the Qualified Default Investment Asset (QDIA).
• This conversion is not a taxable event.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook regarding the acquisition, with a focus on continuity and benefits for stakeholders. However, there are inherent risks associated with the transaction, which temper the overall sentiment.

Positives

• The acquisition provides a defined exit strategy for shareholders at a price of $31.35 per share.
• The company's day-to-day operations and FY25 goals will remain unchanged, ensuring business continuity.
• The ESPP will continue until December 31, 2024, allowing employees to benefit from the merger consideration.
• KSOP shares will be converted to cash within the 401k plan, ensuring no loss of value for employees.

Negatives

• The ESPP will be discontinued after December 31, 2024, removing a benefit for employees.
• The company will transition from a public to a private entity, which may reduce transparency.

Risks

• The merger may not be completed within the anticipated timeframe or at all due to regulatory or shareholder issues.
• The merger could disrupt current operations and divert management's attention.
• The company may face challenges in retaining key personnel and maintaining relationships with customers and suppliers.
• The stock price may decline significantly if the merger is not completed.
• There are risks associated with legal proceedings related to the merger.
• The company is dependent on suppliers and faces risks related to distribution, technology, and market obsolescence.
• There are risks associated with cyber-security attacks and the use of artificial intelligence.
• The company is exposed to risks in the dental and animal health supply markets, including competition and consolidation.
• The company faces risks related to health care regulations, litigation, and international operations.
• Uncertain macro-economic conditions, including inflationary pressures, pose a risk.

Future Outlook

The company expects the transaction to close in its fiscal fourth quarter of 2025, subject to shareholder and regulatory approvals. Patterson anticipates operating in the same manner after the transaction closes.

Management Comments

• Patterson CEO Don Zurbay sent a memo to all Patterson employees sharing the news of the acquisition.
• Management believes the transaction will have positive benefits for Patterson, its employees, and customers.
• Management emphasizes that day-to-day responsibilities and FY25 goals remain the same.
• Management states that the company's purpose, vision, values, and service to customers will remain unchanged.

Industry Context

The acquisition of Patterson Companies by Patient Square Capital reflects a trend of private equity firms investing in healthcare companies. This move could be driven by the desire to leverage Patterson's established market position and improve operational efficiencies.

Comparison to Industry Standards

• The acquisition price of $31.35 per share is a premium over the recent trading price of Patterson Companies, which is typical in such transactions.
• Similar acquisitions in the healthcare sector have seen private equity firms focusing on companies with strong market positions and growth potential.
• The transaction is in line with the trend of consolidation in the dental and animal health supply markets.
• Comparable companies in the healthcare distribution space include Henry Schein and Cardinal Health, which have also seen significant M&A activity.

Stakeholder Impact

• Shareholders will receive $31.35 per share upon completion of the merger.
• Employees will continue to work under the same conditions and focus on FY25 goals.
• Customers will continue to receive the same level of service.
• Suppliers will maintain their existing relationships with Patterson.

Next Steps

• Prepare proxy materials for shareholder vote.
• Schedule a meeting of shareholders to vote on the transaction.
• Make required regulatory filings.
• Close the transaction in the fiscal fourth quarter of 2025.

Key Dates

Keywords

acquisition, merger, Patient Square Capital, Patterson Companies, shareholders, ESPP, KSOP, private equity, healthcare, regulatory filings